Tacalyx GmbH
Magnusstraße 11, 12489 Berlin
+49 30 40723710
Focus
The biotechnology company Tacalyx focuses on the discovery and development of novel cancer therapies that target tumor-specific sugar structures, so-called TACAs (Tumor Associated Carbohydrate Antigens). In many types of cancer, TACAs are formed by malignant transformation in a microevolutionary process and are responsible for metastasis of the tumor, formation of new blood vessels for its supply, and suppression of the body's immune response. Using innovative methods and platform technologies, antibody-based therapeutics are being developed against this challenging class of substances, which Tacalyx uses to address difficult-to-treat cancer indications.